Judith Kelleher-Andersson, Ph.D.
Founder, President and Chief Executive Officer (CEO)
"A therapy that is only neuroprotective will never be sufficient to halt or reverse neurodegenerative disease progression." I came to this realization after working in the neuroscience field for over 20 years as a graduate student, as a post-graduate fellow and after working at three biotech companies, where I directed the discovery of therapeutics aimed at Alzheimer's disease and other neurodegenerative disorders. MORE
Neuronascent, Inc. has discovered and is developing disease-modifying therapeutics for some of the most difficult to treat brain disorders that include Alzheimer's disease, Parkinson's disease and Down syndrome.
Our lead candidate for Alzheimer's and potentially Parkinson's disease, NNI-362, not only shows efficacy, by increasing the number of new neurons that survive to maturity that is associated with a reversal in behavioral impairment, but is also shown to be safe in all FDA required GLP safety tests. This "neuron-regenerative" agent crosses into brain, following oral administration and increases the number of new neurons through a unique mechanism-of-action, suggesting a first-in-class therapeutic aimed at reversing Alzheimer's disease.
NEWS & EVENTS
Nov 2017 Neuronascent Granted Composition of
Matter Patent in Europe for Oral Neuron Regenerative Technology READ MORE
Oct 2017 Opened Fundable Project READ MORE
Apr 2017 Neuronascent Appoints New Board Member. READ MORE
Jan 2017 Neuronascent Announces Third US Patent Issued Covering Therapeutics for Neurodegenerative and Neuropsychiatric Disorders. READ MORE
Feb 2016 Neuronascent's Research Tool Aimed at Stroke Tolerance is Characterized in 2016 Publication. READ MORE
Apr 2015 Neuronascent Secures Financing for Development of Its Alzheimer's Therapeutic. READ MORE
Feb 2015 Neuronascent Announces Expanded Patent Coverage In US and Russia For Its Alzheimer's Disease and Down Syndrome Therapeutics. READ MORE